Leflunomide-Induced Interstitial Lung Disease: A Case Report

Creative Commons License

Guzel A., Köksal N., Gok A., Elmalı M.

EURASIAN JOURNAL OF PULMONOLOGY, cilt.17, sa.1, ss.67-69, 2015 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.5152/ejp.2014.93357
  • Dergi Adı: EURASIAN JOURNAL OF PULMONOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.67-69
  • Anahtar Kelimeler: Adverse reaction, drug, interstitial lung disease, leflunomide, RHEUMATOID-ARTHRITIS, INDUCED PNEUMONITIS, THERAPY, PATIENT
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Leflunomide (LEF) induced interstitial pneumonitis is a very rare condition but potentially fatal. We report a case of LEF induced interstitial pneumonitis. A 63-year-old woman followed-up for 37 years with the diagnosis of rheumatoid arthritis treated with LEF (20 mg/day) since 5 months were admitted to our hospital with cough, dyspnea, fever, and dark sputum. Chest radiography represented bilateral alveolar consolidation. High-resolution computed tomography demonstrated diffuse ground-glass appearance and interlobular septal thickening. Since the patient's clinics and radiologic findings improved dramatically after the cessation of LEF and recieving oral steriod therapy, she was diagnosed as drug-induced interstitial lung disease. In conclusion, when nonspecific clinical signs such as respiratory distress, cough and fever seen during the use of LEF, drug-induced interstitial lung disease should be kept in mind for the differantial diagnosis.